EFFECTS OF PIMOZIDE ON COGNITION IN CHILDREN WITH TOURETTE SYNDROME - INTERACTION WITH COMORBID ATTENTION-DEFICIT HYPERACTIVITY DISORDER

被引:26
作者
SALLEE, FR
SETHURAMAN, G
ROCK, CM
机构
[1] MED UNIV S CAROLINA,DEPT BIOMETRY,CHARLESTON,SC 29425
[2] VIRGINIA POLYTECH INST & STATE UNIV,DEPT PSYCHOL,BLACKSBURG,VA 24061
关键词
TOURETTE SYNDROME; COGNITION; ATTENTION DEFICIT HYPERACTIVITY DISORDER;
D O I
10.1111/j.1600-0447.1994.tb01546.x
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Pimozide, a dopamine receptor antagonist, dopamine uptake inhibitor and L-type calcium channel blocker, is used in children suffering from Tourette syndrome (TS), but its effect on frequently comorbid attention deficit hyperactivity disorder (ADHD) is unknown. We have characterized the cognitive effects of pimozide and haloperidol in TS in relation to comorbid ADHD. Sixty-six consecutive outpatients with TS (DSM-III-R), ages 7-16, were randomly assigned to pimozide, haloperidol or medication-free clinical treatment and evaluated cognitively after 6 weeks. Continuous performance task (CPT) and memory search efficiency were compared across treatments. Treatment, comorbid ADHD and their interaction were significant on the CPT task. Pimozide treatment was superior to haloperidol and improved memory search efficiently over the no-drug condition.
引用
收藏
页码:4 / 9
页数:6
相关论文
共 40 条
[1]  
ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO
[2]  
BORNSTEIN RA, 1991, AM J PSYCHIAT, V148, P468
[3]  
BRUNN RD, 1988, AM J PSYCHIAT, V145, P621
[4]  
CASAT CD, 1989, PSYCHOPHARMACOL BULL, V25, P198
[5]   DIFFERENTIAL-EFFECTS OF HALOPERIDOL AND CLOZAPINE ON ATTENTION [J].
CHEAL, ML .
PSYCHOPHARMACOLOGY, 1984, 84 (02) :268-273
[6]  
COHEN DJ, 1992, PSYCHIAT CLIN N AM, V15, P109
[7]  
ENYEART JJ, 1990, MOL PHARMACOL, V37, P752
[8]  
ERENBERG G, 1988, PEDIATR ANN, V17, P1
[9]   METHYLPHENIDATE IN HYPERACTIVE BOYS WITH COMORBID TIC DISORDER .2. SHORT-TERM BEHAVIORAL-EFFECTS IN SCHOOL SETTINGS [J].
GADOW, KD ;
NOLAN, EE ;
SVERD, J .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1992, 31 (03) :462-471
[10]  
GIROS B, 1992, MOL PHARMACOL, V42, P383